Eye implant could restore sight after retinal vein blockage

NCT ID NCT07708142

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 3 trial tests a single injection of SMO1, a dexamethasone implant placed inside the eye, for people with macular edema (swelling) caused by a blocked retinal vein. The study compares SMO1 to an existing dexamethasone implant to see which better improves vision and reduces swelling over six months. Participants are adults with branch or central retinal vein occlusion and significant vision loss. The goal is to find a safe, effective treatment to help restore sight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a dexamethasone intravitreal implant (SMO1)
What this could lead to
If successful, SMO1 could offer a new treatment option for people with vision loss due to retinal vein occlusion, potentially improving sight with a single injection.
What could go wrong
This is a phase 3 trial comparing SMO1 to an existing drug, so it may not prove superior. Eye injections carry risks like infection, increased eye pressure, or cataract formation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINAL VEIN OCCLUSION WITH MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kyung Hee University Hospital at Gangdong

    RECRUITING

    Seoul, Gangdong-gu, 05278, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••